Skip to main content
SpringerLink
Log in

Enzastaurin, a Targeted PKCβ Inhibitor, in Relapsed or Refractory DLBCL: A Promising New Strategy Based on Gene Expression Signature

  • Clinical Trials Report
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Abramson JS, Shipp MA: Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005, 106:1164–1174.

    Article  PubMed  CAS  Google Scholar 

  2. Nademanee A, Forman S, Molina A, et al.: A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005, 106:2896–2902.

    Article  PubMed  CAS  Google Scholar 

  3. Inwards DJ, Cilley JC, Winter JN: Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma. Best Pract Res Clin Haematol 2006, 19:669–684.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Carol S. Portlock MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Portlock, C.S. Enzastaurin, a Targeted PKCβ Inhibitor, in Relapsed or Refractory DLBCL: A Promising New Strategy Based on Gene Expression Signature. Curr Oncol Rep 9, 371–372 (2007). https://doi.org/10.1007/s11912-007-0049-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0049-5

Keywords

Search

Navigation